

This is the peer reviewed version of the following article:

EDIN and N-PASS pain scale comparison in asphyxiated newborns treated with therapeutic hypothermia / Lugli, L; Garetti, E; Roversi, Mf; Bianchini, A; Cuoghi Costantini, R; Guidotti, I; De Novellis, M; Spaggiari, E; Lago, P; Berardi, A. - In: FRONTIERS IN PAIN RESEARCH. - ISSN 2673-561X. - (2026), pp. 7-17. [10.3389/fpain.2026.1783611]

Terms of use:

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

07/05/2026 19:49

(Article begins on next page)



OPEN ACCESS

EDITED BY
Line Caes,
University of Stirling, United Kingdom

REVIEWED BY
Matthias Nissen,
Ruhr University Bochum, Germany
Guzide UGUCU,
Mersin University, Türkiye

*CORRESPONDENCE
Licia Lugli
✉ lugli.licia@aoou.mo.it
✉ licia.lugli@gmail.com

RECEIVED 08 January 2026
REVISED 14 February 2026
ACCEPTED 17 February 2026
PUBLISHED 23 March 2026

CITATION

Lugli L, Garetti E, Roversi MF, Bianchini A, Cuoghi Costantini R, Guidotti I, De Novellis M, Spaggiari E, Lago P and Berardi A (2026) EDIN and N-PASS pain scale comparison in asphyxiated newborns treated with therapeutic hypothermia.
Front. Pain Res. 7:1783611.
doi: 10.3389/fpain.2026.1783611

COPYRIGHT

© 2026 Lugli, Garetti, Roversi, Bianchini, Cuoghi Costantini, Guidotti, De Novellis, Spaggiari, Lago and Berardi. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

EDIN and N-PASS pain scale comparison in asphyxiated newborns treated with therapeutic hypothermia

Licia Lugli^{1*}, Elisabetta Garetti¹, Maria Federica Roversi¹, Arianna Bianchini¹, Riccardo Cuoghi Costantini², Isotta Guidotti¹, Michele De Novellis¹, Eugenio Spaggiari¹, Paola Lago³ and Alberto Berardi¹

¹Neonatology and Neonatal Intensive Care Unit, University Hospital of Modena, Modena, Italy, ²Statistic Unit, University Hospital of Modena, Modena, Italy, ³Neonatology Unit, Cà Foncello Hospital Treviso, Treviso, Italy

Background: Therapeutic hypothermia (TH) is the standard treatment for moderate to severe hypoxic–ischemic encephalopathy (HIE), yet pain assessment during TH remains challenging. This study compares two validated pain scales in asphyxiated newborns undergoing TH and receiving fentanyl analgesia.

Methods: Twenty term infants with HIE treated with TH were enrolled. Pain was assessed using EDIN and N-PASS, while sedation was monitored using the N-PASS sedation subscale.

Results: N-PASS pain and sedation scores significantly decreased by day 3, whereas EDIN scores showed no significant temporal change. Effective analgesia significantly increased over time, either when defined based on EDIN (OR 3.12, $p = 0.002$) and on N-PASS (OR 3.06, $p = 0.007$), while N-PASS sedation did not show a time-dependent association. No scale showed a significant association with fentanyl dosage. A moderate positive correlation was found between EDIN and N-PASS pain scores ($r = 0.409$, $p < 0.001$). Sedation targets were achieved in only 40%–50% of assessments, with early undersedation and later oversedation observed.

Conclusions: EDIN and N-PASS pain scores demonstrate moderate concordance, but capture different dimensions of neonatal pain during TH. N-PASS appears more sensitive to temporal changes, likely due to its combined behavioral and physiological components, whereas EDIN may be affected by hypothermia-related behavioral suppression.

KEYWORDS

asphyxia, EDIN, N-PASS, pain, therapeutic hypothermia

Highlights

- This study compares the EDIN and N-PASS pain scales in asphyxiated newborns undergoing therapeutic hypothermia, where analgesia is particularly challenging.
- Pain and sedation assessments showed different temporal patterns, with N-PASS more responsive to change than EDIN, while the two scales still demonstrated a moderate correlation.
- Findings underscore the difficulty of maintaining stable analgesia and sedation during therapeutic hypothermia and the need for improved assessment tools in this context.

Introduction

Neonatal encephalopathy resulting from perinatal asphyxia remains one of the leading causes of neonatal mortality and long-term neurological morbidity worldwide (1–4). Over the past two decades, therapeutic hypothermia (TH) has become the standard of care for term newborns with moderate to severe hypoxic–ischemic encephalopathy (HIE). Robust evidence from randomized controlled trials and meta-analyses has shown that TH significantly reduces mortality and the risk of severe neurodevelopmental impairment (1–8). Despite its neuroprotective benefits, TH is associated with several physiological and clinical challenges (9–13). During the cooling phase, newborns may experience stress, discomfort, and pain, which can negatively affect hemodynamic stability, metabolic balance, and potentially the overall therapeutic efficacy of hypothermia. Moreover, untreated pain or stress may trigger adverse neuroendocrine responses, whereas excessive use of sedatives and analgesics to control discomfort may also carry potential risks for the developing brain. Accurate pain assessment therefore plays a crucial role in the management of infants undergoing TH (9–13). However, pain evaluation in neonates with HIE is particularly complex. Neurological depression, sedation, and therapeutic hypothermia itself can affect behavioral and physiological responses, making standard pain assessment less reliable. For this reason, several validated neonatal pain scales have been developed and applied in clinical practice, each with definite strengths and limitations, none of them developed specifically for TH (9–13). There is currently no consensus regarding which scale provides the most accurate and clinically useful assessment of pain in neonates undergoing therapeutic hypothermia for HIE. Comparative studies are limited, and the reliability of some tools may be affected by the altered neurological and physiological state of these infants. For this reason, the present study aimed to compare two neonatal pain assessment scales—the Neonatal Pain, Agitation and Sedation Scale (N-PASS) and the Échelle Douleur Inconfort Nouveau-Né (EDIN)—in the specific context of TH for HIE (14–18). We hypothesized that although EDIN and N-PASS scores would be correlated, the multidimensional N-PASS scale—which incorporates physiological parameters—would prove to be a superior and more clinically useful tool for monitoring both pain and sedation in neonates undergoing hypothermia therapy. By evaluating their consistency and performance over time, we aimed to contribute to the identification of the most appropriate tool for optimal pain management in this vulnerable population.

Methods

Patients

Newborns affected by moderate to severe HIE and treated with TH at the NICU of the University Hospital of Modena since 1 January 2022 to December 2024 were eligible for this prospective cohort study. The selection of patients for TH was based on previously established criteria: (1) gestational age \geq 37 weeks; (2) intrapartum asphyxia, defined by at least one of the

following: an Apgar score \leq 5 at 10 min, ventilation with an endotracheal tube or a mask for at least 10 min, or metabolic acidosis within 60 min of birth (cord pH or any arterial/venous pH \leq 7.0 or base defect \geq 12 mmol/L); (3) neonatal encephalopathy evaluated within 1 h of birth according to Sarnat modified criteria; and (4) moderate to severe EEG polygraphic (pEEG) or amplitude-integrated EEG (aEEG) abnormalities (3, 4, 13, 19–22). Other exclusion criteria were congenital malformations, chromosomal abnormalities, either suspected or confirmed metabolic disorders, sepsis or central nervous system infections, and different causes of asphyxia (i.e., sudden, unexpected postnatal collapse). Patients were cooled to a rectal temperature of 33.5 °C for 72 h (CritiCool MTRE, Charter Kontron, Milton Keynes, UK). After 72 h of cooling, slow, controlled, and monitored rewarming was started, increasing the set temperature by 0.5 °C every hour. In this way, the patient achieved a 36 °C core temperature in about 5–6 h. If any complication occurred during this period (i.e., seizure), rewarming was transiently interrupted and restarted when clinically indicated (3, 4, 13, 19–21). Every enrolled patient was administered an indwelling double-lumen umbilical catheter with one of the two lumina dedicated to fentanyl infusion. Enrolled newborns received a fentanyl loading dose of 2 mcg/kg as an intravenous bolus (in 20 min), which was immediately followed by 1 mcg/kg/h as a continuous infusion during TH and the rewarming phase. The continuous fentanyl infusion could be increased by 25%–50% if discomfort or pain arose. Shivering, a 20% increase in heart rate over the baseline, facial grimaces, and EDIN score $>$ 6 or N-PASS scores $>$ 3 were considered signs of discomfort or pain (13, 22).

Pain measurement

Pain assessments were performed by the bedside nurses (BNs) responsible for the clinical care of each infant. All participating BNs held specialized qualifications in neonatal intensive care. Prior to the initiation of the study, the entire nursing staff of the unit underwent a standardized, structured training program on the administration of both the EDIN and N-PASS scales. This training consisted of a theoretical session reviewing the scoring criteria for each item on both scales, followed by a practical calibration phase. During the calibration phase, nurses independently scored a series of standardized video recordings of neonates (not included in the study) exhibiting varying states of pain, agitation, and sedation. Their scores were then compared against a pre-determined gold-standard scoring provided by two senior specialists with over 10 years of NICU experience and certified expertise in neonatal pain assessment. Discrepancies were discussed in a group session to reach a consensus on correct application, with the goal of maximizing inter-rater agreement. To maintain consistency throughout the data collection period, refresher training sessions were held quarterly. EDIN and N-PASS scores were recorded simultaneously three times daily (T1, T2, T3) during hypothermia and rewarming, coinciding with the nursing staff's routine assessment schedule (13). It should be noted that while active cooling lasted 72 h (Days 1–3), “Day 4” in this analysis refers to the period of rewarming, during which infants became

normothermic but remained critically ill in the NICU. EDIN is a unidimensional validated scale using five behavioural indicators of prolonged pain: facial activity, body movements, quality of sleep, quality of contact with nurses, and consolability (18). Each indicator is scored from 0 to 3, resulting in a total score ranging from 0 to 15. A score greater than 6 is generally considered indicative of the presence of pain, warranting clinical attention and potential intervention (13, 18). N-PASS algometric scale encompasses five indicators: (1) crying/irritability (with a silent cry observed in intubated infants scored as a cry), (2) behavioral state, (3) facial expression, (4) extremities/tone, and (5) vital signs. The criteria are assigned values of 0, 1, or 2 (for pain/agitation) and 0, -1, or -2 (for sedation) (14–17). The N-PASS pain scores range from 0 to 10 for term newborns. A N-PASS score >3 indicates moderate pain. The N-PASS score for sedation ranges from 0 to -10 (moderate sedation: an N-PASS score between -2 and -5; profound sedation: an N-PASS score between -5 and -10) (14–17). In this study, the targeted level of sedation was moderate sedation (N-PASS score between -2 and -5).

To standardize the context of assessment as much as possible within clinical constraints, the following protocol was established:

1. N-PASS pain score and EDIN score: these assessments were conducted while the infant was at rest, ideally at least 30 min after a scheduled caregiving intervention (e.g., diaper change, suctioning, repositioning) or a painful procedure. The bedside nurse observed the infant for a full 2-minute period without direct stimulation before assigning scores. This approach aimed to capture a “baseline” level of prolonged discomfort or pain, as intended by these scales.
2. N-PASS sedation score: In contrast, the N-PASS sedation subscale was evaluated specifically during and immediately after routine nursing maneuvers, such as gentle handling for assessment or diaper change. This approach is aligned with the scale’s validation, as responsiveness to handling is a key behavioral indicator of sedation depth. The score reflected the infant’s lowest level of responsiveness observed during the maneuver.

This protocol was designed to ensure that pain/discomfort scores were not artificially inflated by procedural stress, while sedation scores were evaluated in a context that would elicit a behavioral response, thereby providing a more accurate and clinically relevant assessment of each construct.

Pain and sedation assessments (T1, T2, T3) continued for the rewarming period (T1 in Day 4) to capture the immediate post-hypothermia phase.

For the purpose of this study, we defined clinical outcomes based on established thresholds for each scale:

1. Effective analgesia: a state where the pain score was at or below the recognized threshold for clinically significant pain. This was defined as an EDIN score ≤ 6 or an N-PASS pain score ≤ 3 .
2. Ineffective Analgesia/Presence of Pain: an EDIN score > 6 or an N-PASS pain score > 3 .

3. Target Sedation: a N-PASS sedation score between -2 and -5, representing a moderate, clinically desirable level of sedation.

These binary outcomes (effective vs. ineffective analgesia; target vs. non-target sedation) were used in the generalized mixed-effect regression models to analyze changes over time and associations with fentanyl dosage.

Statistical analysis

Descriptive statistics were computed for all analyzed variables: continuous variables were described as mean \pm standard deviation (SD), whereas absolute frequencies and percentages were used for categorical variables. Statistical analyses were performed to evaluate the relationship between pain assessment scales and changes over time. To examine the correlation between pain scores, repeated measures correlation Pearson coefficient (r_{rm}) was estimated and reported with 95% confidence intervals (CI) and p -value. R-squared (R^2) was also computed. Univariable generalized mixed-effect regression models were used to investigate the variations across observational periods of pain and sedation scores. Moreover, multivariable generalized mixed-effect models were used to assess the association between effective analgesia and time, adjusting for fentanyl dosage. To deal with repeated measures on the same infants, a random intercept term was included in all these models. Obtained results were reported in terms of mean differences (MD) or Odds ratios (OR), with 95% CI and p -values. Bland-Altman analysis for agreement was also constructed to visualize the limits of agreement between the two scales. The mean difference (bias) between N-PASS and EDIN scores and its 95% CI were calculated. The 95% limits of agreement (LoA; bias \pm 1.96 SD of the differences) were derived to quantify the expected range of disagreement between the two instruments in the study population (23). Scores were also categorized into clinically relevant bins: no/mild pain (EDIN ≤ 6 & N-PASS ≤ 3) and moderate/severe pain (EDIN > 6 or N-PASS > 3). The observed agreement and Cohen’s kappa coefficient (κ) with its 95% CI were calculated to assess the reliability of this clinical classification. The significance level alpha was set at 0.05.

All analyses were carried out using R version 4.3.2 (The R Foundation for Statistical Computing, Austria, Vienna, 2023).

Results

Twenty infants were enrolled in the study (12 males and 8 females). The mean gestational age was 39.1 ± 1.4 weeks, and the mean birth weight was $3,420 \pm 560$ g. At enrollment, seventeen infants had moderate and three had severe encephalopathy. Two infants developed seizures and received phenobarbitone. Table 1 displays the administered fentanyl dose, as well as the EDIN and N-PASS scores, over the study period.

Fentanyl dosage was escalated during the study period in accordance with the study protocol. The mean N-PASS pain and sedation scores were significantly lower on day 3 than on day 1, whereas EDIN scores did not differ significantly (Table 1).

TABLE 1 NPASS scores, EDIN scores and fentanyl administered doses during study period.

| Variable | Time | Estimate | Std. Error | 95% Conf. Int. | | p-value |
|-------------------------------|---|----------|------------|----------------|-------|---------|
| N-PASS Pain | Mean Day 1 | 2,40 | 0,29 | 1,82 | 2,97 | |
| | Mean difference between Day 2 and Day 1 | -0,49 | 0,31 | -1,10 | 0,12 | 0,121 |
| | Mean difference between Day 3 and Day 1 | -1,07 | 0,32 | -1,69 | -0,45 | 0,001 |
| | Mean difference between Day 4 and Day 1 | -0,78 | 0,47 | -1,70 | 0,14 | 0,098 |
| N-PASS Sedation | Mean Day 1 | -4,22 | 0,46 | -5,12 | -3,33 | |
| | Mean difference between Day 2 and Day 1 | -0,60 | 0,36 | -1,31 | 0,11 | 0,101 |
| | Mean difference between Day 3 and Day 1 | -1,08 | 0,36 | -1,79 | -0,37 | 0,003 |
| | Mean difference between Day 4 and Day 1 | -1,67 | 0,55 | -2,74 | -0,60 | 0,003 |
| EDIN | Mean Day 1 | 2,98 | 0,42 | 2,17 | 3,80 | |
| | Mean difference between Day 2 and Day 1 | 0,15 | 0,50 | -0,83 | 1,13 | 0,761 |
| | Mean difference between Day 3 and Day 1 | -0,71 | 0,51 | -1,70 | 0,28 | 0,162 |
| | Mean difference between Day 4 and Day 1 | -0,81 | 0,71 | -2,21 | 0,59 | 0,260 |
| Fentanyl dosage (mcg/kg/h) | Mean Day 1 | 1,42 | 0,08 | 1,27 | 1,57 | |
| | Mean difference between Day 2 and Day 1 | 0,37 | 0,06 | 0,25 | 0,50 | <0,001 |
| | Mean difference between Day 3 and Day 1 | 0,36 | 0,06 | 0,24 | 0,49 | <0,001 |
| | Mean difference between Day 4 and Day 1 | -0,25 | 0,09 | -0,43 | -0,08 | 0,005 |

Therapeutic hypothermia was maintained at 33.5 °C for 72 h (Days 1–3). Day 4 represents the period of controlled rewarming. Mean differences and their standard error were estimated through univariable linear mixed-effect regression models, which included a random intercept term to account for repeated measures on the same subjects, and time (days) as a fixed effect. Std. Error, Standard error; Conf. Int., Confidence interval.


Figures 1A, 2A, 3A show mean values and 95% confidence intervals for EDIN, n-PASS pain and N-PASS sedation respectively. Figures 1B, 2B show effective analgesia, assessed using the EDIN and N-PASS pain scale, respectively, whereas Figure 3B shows effective sedation, assessed using the N-PASS sedation scale. Effective analgesia was associated with time for both EDIN (OR = 3.12; 95% CI 1.36–7.16; $p = 0.007$) and N-PASS pain (OR = 3.06; 95% CI 1.51–6.16; $p = 0.002$) scores. In contrast N-PASS sedation was not associated with time (OR = 1.41; 95% CI 0.97–2.04; $p = 0.069$). Changes over time in any of the scales were not associated with the administered fentanyl dosage. A significant correlation was found between EDIN and N-PASS pain scores ($r_{rm} = 0.409$, 95% CI 0.242–0.552, $p < 0.001$; $R^2 = 0.167$) (Figure 4).

The Bland-Altman analysis revealed a mean difference (bias) of -0.61 (95% CI: -0.85 to -0.36), indicating that, on average, N-PASS scores were 0.61 points lower than EDIN scores. The 95% limits of agreement were wide, ranging from -5.87 to 4.65. This indicates that for an individual assessment, the N-PASS score could be as much as 5.87 points lower or 4.65 points higher than the EDIN score. When classifying pain states, the two scales showed an observed agreement of 72.1% for distinguishing no/mild vs. moderate/severe pain. However, Cohen's kappa was 0.32 (95% CI: 0.19–0.45), indicating only fair agreement beyond what would be expected by chance.

Discussion

This study provides a comparative analysis of two neonatal pain assessment scales—the EDIN and N-PASS—in a cohort of asphyxiated newborns undergoing TH for HIE. Our findings

demonstrate a statistically significant, moderate positive correlation between EDIN and N-PASS pain scores, indicating that these scales measure related, yet distinct, aspects of the pain experience in this vulnerable population. The observed correlation suggests that both tools are sensitive to changes in neonatal pain states during TH. However, the moderate strength of the correlation implies that EDIN and N-PASS may capture different dimensions of pain or may differ in their sensitivity to specific pain indicators under hypothermic conditions. The N-PASS scale, which incorporates both physiological and behavioral parameters, demonstrated a significant reduction in pain scores over the treatment period, aligning with escalating fentanyl administration. In contrast, EDIN scores, which focus exclusively on behavioral indicators of prolonged pain, remained relatively stable over time. This divergence may be attributed to the differential effects of TH and sedation on behavioral vs. composite (behavioral and physiological) pain responses. Hypothermia itself can suppress behavioral manifestations of pain, such as facial activity and body movements, which form the core of the EDIN scale (10–13). Conversely, N-PASS includes vital sign components that may remain responsive even under hypothermic and sedated conditions. The finding that effective analgesia, as measured by both scales, was associated significantly with time but not with the administered fentanyl dosage warrants careful consideration. This suggests that the natural evolution of HIE, rather than pharmacological intervention alone, may significantly affect pain expression during TH. As encephalopathy develops over time, neurological responsiveness may change, independently affecting pain scale measurements (10–13, 22, 24). While the natural evolution of HIE could be a primary driver of changing pain expression, a critical methodological factor must also be acknowledged. Our study, by



design, reflected standard clinical protocol in which the fentanyl infusion was actively titrated in response to elevated pain scores (EDIN > 6 or N-PASS > 3). This creates a fundamental feedback loop: higher pain scores trigger dose increases, which, if effective, should subsequently lower the pain scores. In such a dynamic system, a simple cross-sectional or longitudinal association between the absolute dose and the concurrent score is inherently obscured. The administered dose at any point is a function of the prior pain state, not an independent variable. Therefore, the lack of a direct statistical association in our models does not

imply that fentanyl was ineffective; rather, it reflects the reality of protocolized, responsive analgesia where the dose is continually adjusted to achieve a target outcome (pain score below threshold). This mechanistic complexity makes it difficult to isolate a classic pharmacokinetic/pharmacodynamic relationship from observational data in this setting. Future studies aiming to define optimal dosing might consider methodologies that can account for this temporal dependency, such as time-lagged analyses or modeling dose as a time-varying covariate with careful adjustment for the indication (pain score) (17, 22).




FIGURE 2 (A) N-PASS pain score mean values and confidence intervals during the study period. The N-PASS pain score is assessed three times a day on days 1, 2, and 3 (T1, T2, T3) and once a day on day 4 during rewarming. The Y axis shows N-PASS pain score mean values and 95% confidence intervals. (B) Effective analgesia assessed using the N-PASS pain scale. The N-PASS pain score is assessed three times a day on days 1, 2, and 3 (T1, T2, T3) and once a day on day 4 during rewarming. The Y axis shows % of patients with effective analgesia, as evaluated by N-PASS pain score. Effective analgesia: N-PASS pain score ≤ 3 . Ineffective analgesia: N-PASS pain score > 6 .

Nevertheless, in the specific context of TH-managed neonates, both scales offer distinct advantages. The N-PASS provides a comprehensive assessment by integrating physiological parameters with behavioral indicators, potentially offering a more complete picture of the neonate’s state, particularly in sedated or neurologically depressed infants. Its bidirectional scoring system also allows simultaneous monitoring of both pain and sedation, which is particularly valuable in this

population where both states commonly coexist and require careful balancing. The EDIN scale, developed specifically for assessing prolonged pain in neonates, may be particularly suited for detecting more subtle, persistent discomfort during the extended TH protocol. Its exclusive focus on behavioral indicators might make it less susceptible to confounding by physiological instability common in HIE patients. However, this same characteristic may also limit its sensitivity in severely




FIGURE 3 (A) N-PASS sedation mean values and confidence intervals during the study period. The N-PASS sedation score is assessed three times a day on days 1, 2, and 3 (T1, T2, T3) and once a day on day 4 during rewarming. The Y axis shows N-PASS pain score mean values and 95% confidence intervals. (B) Effective sedation assessed using the N-PASS sedation scale. The N-PASS sedation is assessed three times a day on days 1, 2, and 3 (T1, T2, T3) and once a day on day 4 during rewarming. The Y axis shows % of patients with effective analgesia, as evaluated by N-PASS sedation score. Moderate sedation: N-PASS sedation between -2 and -5. Profound: N-PASS sedation < -5. Mild sedation: N-PASS sedation > -2.

encephalopathic infants who demonstrate minimal behavioral responses.

In addition, while EDIN and N-PASS scores showed moderate correlation ($r_{rm} = 0.409$), agreement analyses revealed they are not clinically interchangeable. The Bland-Altman plot

demonstrated wide limits of agreement, indicating that for individual infants, scores could differ by nearly 6 points—a clinically significant discrepancy that could lead to different treatment decisions. Furthermore, categorical agreement for pain classification was only fair ($\kappa = 0.32$). This supports our




FIGURE 4

EDIN and N-PASS pain score correlation. The y-axis represents the N-PASS pain score. The x-axis represents EDIN score. $r_{rm} = 0.409$, 95% CI 0.242 to 0.552, $p < 0.001$.

interpretation that the scales capture different dimensions of the neonatal experience during TH. Notably, EDIN's sensitivity to behavioral manifestations may be significantly attenuated by hypothermia, whereas N-PASS—with its combined behavioral and physiological framework—provides a more robust and clinically actionable assessment in this unique therapeutic context. Further consideration emerges from the analysis of sedation. Despite the protocol targeting moderate sedation (N-PASS sedation score between -2 and -5), our data show that patients maintained an optimal sedation level in only 40%–50% of the cases. A temporal analysis revealed a distinct pattern: during the initial phase of therapeutic hypothermia, there was a higher prevalence of patients with N-PASS scores > -2 , indicating insufficient sedation. Conversely, towards the end of the treatment period, a shift was observed towards N-PASS scores < -5 , suggesting a tendency towards deeper sedation. This dynamic profile suggests that maintaining a stable and optimal sedative state during TH is particularly complex. The initial undersedation may be related to the acute stress response and evolving encephalopathy, while the later oversedation could reflect cumulative drug effects or altered pharmacodynamics during prolonged hypothermia and rewarming. This risk is heightened by the significantly reduced hepatic metabolism and renal clearance of fentanyl during sustained hypothermia. This pharmacokinetic alteration, a well-documented effect of cooling, leads to drug accumulation over the 72-hour period, increasing the risk of oversedation (25–27, 30). The pattern of sedation we observed—early undersedation followed by later oversedation—highlights the practical difficulty of maintaining a stable neuroactive drug effect throughout the dynamic phases of cooling. The failure to consistently achieve the sedation target throughout the therapeutic course highlights the need for even closer monitoring and potentially more dynamic, responsive, and personalized sedative titration protocols in this critical population. Our findings align closely with the observations

reported by Üner et al., who similarly documented challenges in maintaining optimal N-PASS sedation scores throughout the course of therapeutic hypothermia, with a tendency toward undersedation early in treatment and oversedation during the later phases (17).

The clinical implications of this pattern are significant. Early undersedation may leave infants exposed to procedural and environmental stress, which can provoke detrimental sympathetic activation, leading to hemodynamic instability, increased cerebral metabolic demand, and potentially undermining the neuroprotective intent of hypothermia. Conversely, later oversedation is also concerning. Profound sedation can mask the clinical signs of evolving seizures, complicate neurological assessment, and may be associated with longer ventilator dependence. Furthermore, accumulating preclinical and clinical evidence suggests that prolonged or excessive exposure to sedatives like fentanyl in the developing brain may carry intrinsic neurotoxic risks or contribute to aberrant neurodevelopment (22, 28, 29). Therefore, the narrow target range for moderate sedation represents a critical balance between mitigating harmful stress and avoiding iatrogenic complications. Our data underscore the practical difficulty of maintaining this balance throughout the 72-hour cooling period and subsequent rewarming, pointing to a clear area for improved, personalized protocols.

Several limitations should be considered when interpreting these results. First, the single-center design and relatively small sample size limit the generalizability of our findings. Second, the blood level measurement of fentanyl was not considered because it was not among the objectives of the study. Furthermore, the potential for assessor bias, despite the use of validated scales, must also be acknowledged, as the nursing staff administering the scales were not blinded to the clinical context or the phase of treatment. Furthermore, the clinical profile of infants undergoing therapeutic

hypothermia for HIE is notably complex and dynamic. In this cohort, two infants developed seizures requiring phenobarbital. We did not statistically adjust for these or other potential confounders—including ventilation status or hemodynamic instability requiring inotropic support—in our models. It is important to recognize that seizures, anticonvulsant therapy, and critical illness can independently affect levels of consciousness, motor tone, and physiological stability, which are core elements of both the EDIN and N-PASS scales. Consequently, the pain and sedation scores presented here represent a composite measure of the infant's clinical state, reflecting not only pain but also the effects of the underlying encephalopathy, concurrent interventions, and the physiological impact of cooling itself. This interpretive challenge is inherent to pain assessment in critically ill neonates and highlights the necessity of contextualizing scale scores within the broader clinical picture (2, 20, 22). Future research should focus on longitudinal assessments of pain scale performance throughout the cooling, rewarming, and recovery phases, as neurological status evolves. Correlation with neurophysiological measures, such as EEG patterns or neuroimaging findings, could provide additional validation. Studies comparing scale performance with biochemical stress markers may further elucidate their biological correlates in the context of TH, and incorporating plasma fentanyl levels could provide additional valuable insight. Despite the limitations of this study, based on our findings and clinical experience, although the two scales correlate, we consider N-PASS to be more suitable in the context of therapeutic hypothermia, for pain and sedation assessment. Its principal advantage lies in its multidimensional design, which integrates physiological parameters that remain responsive despite the behavioral suppression induced by cooling, thereby mitigating a key limitation of purely behavioral scales like EDIN. The clinical utility of N-PASS is further enhanced by its ability to provide a simultaneous, bidirectional evaluation of both analgesia and sedation on a single scale, facilitating more integrated clinical decision-making. Based on this evidence and our subsequent clinical experience, the N-PASS scale has been adopted as the standard assessment tool in our unit for infants undergoing TH.

Conclusion

Both EDIN and N-PASS demonstrate utility for pain assessment in asphyxiated newborns undergoing TH, with a statistically significant correlation supporting their concurrent validity. However, their differential responsiveness over time and to interventions suggests they may capture complementary rather than identical constructs. The N-PASS's incorporation of physiological parameters and its ability to simultaneously assess analgesia and sedation make it particularly valuable in this complex population. Clinicians should recognize that scale selection may influence pain detection and management decisions, and understanding the unique characteristics of each tool is essential for optimal pain management in neonates with HIE receiving TH.

Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving humans were approved by Ethical Committee of Area Vasta Emilia Nord. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants' legal guardians/next of kin.

Author contributions

LL: Conceptualization, Writing – original draft. EG: Conceptualization, Data curation, Writing – review & editing. MR: Data curation, Investigation, Methodology, Writing – original draft. ABi: Data curation, Investigation, Methodology, Writing – original draft. RC: Formal analysis, Methodology, Software, Writing – review & editing. IG: Writing – original draft. MN: Investigation, Writing – original draft. ES: Writing – original draft. PL: Supervision, Validation, Visualization, Writing – review & editing. ABe: Resources, Validation, Visualization, Writing – review & editing.

Funding

The author(s) declared that financial support was not received for this work and/or its publication.

Acknowledgments

We acknowledge all medical and nurse staff who contributed to the study. Excellent Department 2023–2027 of University of Modena and Reggio Emilia.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author LL declared that they were an editorial board member of *Frontiers* at the time of submission. This had no impact on the peer review process and the final decision.

Generative AI statement

The author(s) declared that generative AI was not used in the creation of this manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by *Frontiers* with the support of

artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the

reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fpain.2026.1783611/full#supplementary-material>

References

- Konrad J, Chau V, Selvanathan T. Advances in neonatal hypoxic-ischemic encephalopathy. *Pediatr Clin North Am.* (2025) 72(5):939–55. doi: 10.1016/j.pcl.2025.05.006
- Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE, Davis PG. Cooling for newborns with hypoxic ischaemic encephalopathy. *Cochrane Database Syst Rev.* (2013) 2013(1):Art. No.: CD003311. doi: 10.1002/14651858.CD003311.pub3
- Bedetti L, Lugli L, Guidotti I, Roversi MF, Muttini EDC, Pugliese M, et al. Real-World therapeutic hypothermia for neonatal HIE: neurodevelopmental outcomes and predictors. *Acta Paediatr.* (2025) 114(11):2874–84. doi: 10.1111/apa.70186
- Lugli L, Guidotti I, Pugliese M, Roversi MF, Bedetti L, Della Casa Muttini E, et al. Polygraphic EEG can identify asphyxiated infants for therapeutic hypothermia and predict neurodevelopmental outcomes. *Children (Basel).* (2022) 9(8):1194. doi: 10.3390/children9081194
- Mathew JL, Kaur N, Dsouza JM. Therapeutic hypothermia in neonatal hypoxic encephalopathy: a systematic review and meta-analysis. *J Glob Health.* (2022) 12:04030. doi: 10.7189/jogh.12.04030
- Azzopardi D, Brocklehurst P, Edwards D, Halliday H, Levene M, Thoresen M, et al. The TOBY study. Whole body hypothermia for the treatment of perinatal asphyxial encephalopathy: a randomised controlled trial. *BMC Pediatr.* (2008) 8:17. doi: 10.1186/1471-2431-8-17
- Shankaran S, Laptook AR, Ehrenkranz RA, Tyson JE, McDonald SA, Donovan EF, et al. Whole-body hypothermia for neonates with hypoxic-ischemic encephalopathy. *N Engl J Med.* (2005) 353(15):1574–84. doi: 10.1056/NEJMcp050929
- Simbruner G, Mittal RA, Rohlmann F, Mueche R; neo.nEURO.network Trial Participants. Systemic hypothermia after neonatal encephalopathy: outcomes of neo. nEURO.network RCT. *Pediatrics.* (2010) 126(4):e771–8. doi: 10.1542/peds.2009-2441
- Bäcke P, Bruschetti M, Sibrecht G, Thernström Blomqvist Y, Olsson E. Pharmacological interventions for pain and sedation management in newborn infants undergoing therapeutic hypothermia. *Cochrane Database Syst Rev.* (2022) 11(11):CD015023. doi: 10.1002/14651858.CD015023.pub2
- McPherson C, Frymoyer A, Ortainau CM, Miller SP, Groenendaal F; Newborn Brain Society Guidelines and Publications Committee. Management of comfort and sedation in neonates with neonatal encephalopathy treated with therapeutic hypothermia. *Semin Fetal Neonatal Med.* (2021) 26(4):101264. doi: 10.1016/j.siny.2021.101264
- Bäcke P, Bruschetti M, Blomqvist YT, Olsson E. Interventions for the management of pain and sedation in newborns undergoing therapeutic hypothermia for hypoxic-ischemic encephalopathy (IPSNUT): protocol of a systematic review. *Syst Rev.* (2022) 11(1):101. doi: 10.1186/s13643-022-01982-9
- Joshi M, Muneer J, Mbuagbaw L, Goswami I. Analgesia and sedation strategies in neonates undergoing whole-body therapeutic hypothermia: a scoping review. *PLoS One.* (2023) 18(12):e0291170. doi: 10.1371/journal.pone.0291170
- Lugli L, Spada C, Garetti E, Guidotti I, Roversi MF, Della Casa E, et al. Fentanyl analgesia in asphyxiated newborns treated with therapeutic hypothermia. *J Matern Fetal Neonatal Med.* (2022) 35(25):7764–70. doi: 10.1080/14767058.2021.1937106
- Hillman BA, Tabrizi MN, Gauda EB, Carson KA, Aucott SW. The neonatal pain, agitation and sedation scale and the bedside nurse's assessment of neonates. *J Perinatol.* (2015) 35(2):128–31. doi: 10.1038/jp.2014.154
- Castagno E, Fabiano G, Carmellino V, Cerchio R, De Vito B, Lauria B, et al. Neonatal pain assessment scales: review of the literature. *Prof Inferm.* (2022) 75(1):17–28; English, Italian. doi: 10.7429/pi.2022.751017
- Morgan ME, Kukora S, Nemshak M, Shuman CJ. Neonatal pain, agitation, and sedation scale's use, reliability, and validity: a systematic review. *J Perinatol.* (2020) 40(12):1753–63. doi: 10.1038/s41372-020-00840-7
- Üner IL, Johansen T, Dahle J, Persson M, Stiris T, Andresen JH. Therapeutic hypothermia and N-PASS; results from implementation in a level 3 NICU. *Early Hum Dev.* (2019) 137:104828. doi: 10.1016/j.earlhumdev.2019.104828
- Debillon T, Zupan V, Ravault N, Magny JF, Dehan M. Development and initial validation of the EDIN scale, a new tool for assessing prolonged pain in preterm infants. *Arch Dis Child Fetal Neonatal Ed.* (2001) 85(1):F36–41. doi: 10.1136/fn.85.1.f36
- Ferrari F, Bondi C, Lugli L, Bedetti L, Guidotti I, Banchelli F, et al. The damms EEG score: a new system to quantify EEG abnormalities and predict the outcome in asphyxiated newborns. *J Clin Med.* (2025) 14(6):1920. doi: 10.3390/jcm14061920
- Lugli L, Bariola MC, Guidotti I, Pugliese M, Roversi MF, Bedetti L, et al. Neurodevelopmental outcome of neonatal seizures: a longitudinal study. *Eur J Paediatr Neurol.* (2024) 49:17–26. doi: 10.1016/j.ejpn.2024.01.007
- Lugli L, Balestri E, Berardi A, Guidotti I, Cavalleri F, Todeschini A, et al. Brain cooling reduces the risk of postneonatal epilepsy in newborns affected by moderate to severe hypoxic-ischemic encephalopathy. *Minerva Pediatr (Torino).* (2018) 73(2):150–8. doi: 10.23736/S2724-5276.18.05224-6
- Lugli L, Garetti E, Goffredo BM, Candia F, Crestani S, Spada C, et al. Continuous fentanyl infusion in newborns with hypoxic-ischemic encephalopathy treated with therapeutic hypothermia: background, aims, and study protocol for time-concentration profiles. *Biomedicines.* (2023) 11(9):2395. doi: 10.3390/biomedicines11092395
- Bland JM, Altman DG. Calculating correlation coefficients with repeated observations: part 2—correlation between subjects. *Br Med J.* (1995) 310(6980):633. doi: 10.1136/bmj.310.6980.633 Erratum in: *BMJ* 1996;312(7030):572.
- Gançarski L, Langlet-Muteau C, Rondel J, Escande B, Koenig-Zores C, Kuhn P. Physiological and behavioral stability of newborns on therapeutic hypothermia for hypoxic-ischemic encephalopathy during parental holding. *Pediatr Res.* (2025) 98(4):1283–9. doi: 10.1038/s41390-025-03812-9
- Lutz IC, Allegaert K, de Hoon JN, Marynissen H. Pharmacokinetics during therapeutic hypothermia for neonatal hypoxic ischaemic encephalopathy: a literature review. *BMJ Paediatr Open.* (2020) 4(1):e000685. doi: 10.1136/bmjpo-2020-000685
- Frymoyer A, Bonifacio SL, Drover DR, Su F, Wustoff CJ, Van Meurs KP. Decreased morphine clearance in neonates with hypoxic ischemic encephalopathy receiving hypothermia. *J. Clin. Pharmacol.* (2017) 57:64–76. doi: 10.1002/jcph.775
- Smits A, Annaert P, Van Cruchten S, Allegaert K. A physiology-based pharmacokinetic framework to support drug development and dose precision during therapeutic hypothermia in neonates. *Front. Pharmacol.* (2020) 11:587. doi: 10.3389/fphar.2020.00587
- Durrmeyer X, Vutskits L, Anand KJ, Rimensberger PC. Use of analgesic and sedative drugs in the NICU: integrating clinical trials and laboratory data. *Pediatr Res.* (2010) 67(2):117–27. doi: 10.1203/PDR.0b013e3181c8eef3
- McAdams RM, Berube MW. Emerging therapies and management for neonatal encephalopathy—controversies and current approaches. *J Perinatol.* (2021) 41(4):661–74. doi: 10.1038/s41372-021-01022-9
- Fritz HG, Holzmayr M, Walter B, Moeritz KU, Lupp A, Bauer R. The effect of mild hypothermia on plasma fentanyl concentration and biotransformation in juvenile pigs. *Anesth. Analg.* (2005) 100:996–1002. doi: 10.1213/01.ANE.0000146517.17910.54